Remimazolam for Procedural Sedation During Synchronized Electrical Cardioversion in the Emergency Department
- 1Department of Emergency Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA
- 2Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Abstract
Synchronized electrical cardioversion necessitates procedural sedation to ensure patient comfort and amnesia. Remimazolam is a novel, ultrashort-acting intravenous benzodiazepine with organ-independent esterase metabolism, a favorable safety profile, and flumazenil reversibility. Although, previously described in the electrophysiology laboratory, use of remimazolam has not been reported for electrical cardioversion in the emergency department. In this case, a 67-year-old man with sudden-onset paroxysmal atrial fibrillation presented in symptomatic atrial fibrillation with rapid ventricular response. Following rate and rhythm optimization, the decision was made to proceed with synchronized electrical cardioversion under procedural sedation. After consent was obtained, remimazolam (5 mg intravenously) was administered as a single bolus. Sedation onset occurred at 49 seconds, with adequate depth achieved at 1 minute 37 seconds. A single synchronized biphasic 200 joule electric shock was successfully delivered at 2 minutes 20 seconds, converting the patient to normal sinus rhythm. Eye opening occurred at 3 minutes 50 seconds, with return to baseline orientation at 4 minutes 30 seconds. No apnea, hypoxia, hemodynamic instability, or procedural recall was observed. Continuous end-tidal carbon dioxide monitoring confirmed uninterrupted spontaneous ventilation throughout. The rapid onset, hemodynamic stability, and remarkably brief recovery time observed support its potential as a first-line sedative for emergency department cardioversion. Further prospective study in this setting is warranted.
Related
- Assessment of Direct Oral Anticoagulant Plasma Concentrations Before Elective Electrical Cardioversion
- Hemodynamic and Metabolic Predictors of Unsuccessful Electrical Cardioversion or Early Atrial Fibrillation Recurrence After Electrical Cardioversion
- Factors associated with short- and long-term maintenance of sinus rhythm after successful elective electrical cardioversion
- Condition-Linked Opioid Prescribed-Medicine Events and Subsequent Emergency Department Use Among Adults With Surgical or Procedural Events: A Longitudinal Medical Expenditure Panel Survey Study.
- Atrioventricular Nodal Blocking Agents and Adverse Outcomes Following Cardioversion at a Rural Hospital
BibTeX
@article{bradshaw2026remimazolam,
title = {{Remimazolam for Procedural Sedation During Synchronized Electrical Cardioversion in the Emergency Department}},
author = {Jace C. Bradshaw and Cain Dudek and Taylor Nuse and Chloe Johnson and Jochen Steppan and Matthew J. Levy},
journal = {Journal of the American College of Emergency Physicians open},
year = {2026},
month = oct,
doi = {10.1016/j.acepjo.2026.100506},
url = {https://europepmc.org/article/PMC/PMC13717009},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Remimazolam for Procedural Sedation During Synchronized Electrical Cardioversion in the Emergency Department
AU - Jace C. Bradshaw
AU - Cain Dudek
AU - Taylor Nuse
AU - Chloe Johnson
AU - Jochen Steppan
AU - Matthew J. Levy
PY - 2026
DA - 2026/10/22
JO - Journal of the American College of Emergency Physicians open
DO - 10.1016/j.acepjo.2026.100506
UR - https://europepmc.org/article/PMC/PMC13717009
AB - Synchronized electrical cardioversion necessitates procedural sedation to ensure patient comfort and amnesia. Remimazolam is a novel, ultrashort-acting intravenous benzodiazepine with organ-independent esterase metabolism, a favorable safety profile, and flumazenil reversibility. Although, previously described in the electrophysiology laboratory, use of remimazolam has not been reported for electrical cardioversion in the emergency department. In this case, a 67-year-old man with sudden-onset paroxysmal atrial fibrillation presented in symptomatic atrial fibrillation with rapid ventricular response. Following rate and rhythm optimization, the decision was made to proceed with synchronized electrical cardioversion under procedural sedation. After consent was obtained, remimazolam (5 mg intravenously) was administered as a single bolus. Sedation onset occurred at 49 seconds, with adequate depth achieved at 1 minute 37 seconds. A single synchronized biphasic 200 joule electric shock was successfully delivered at 2 minutes 20 seconds, converting the patient to normal sinus rhythm. Eye opening occurred at 3 minutes 50 seconds, with return to baseline orientation at 4 minutes 30 seconds. No apnea, hypoxia, hemodynamic instability, or procedural recall was observed. Continuous end-tidal carbon dioxide monitoring confirmed uninterrupted spontaneous ventilation throughout. The rapid onset, hemodynamic stability, and remarkably brief recovery time observed support its potential as a first-line sedative for emergency department cardioversion. Further prospective study in this setting is warranted.
SN - 2688-1152
ER -